American Financial Advisors LLC Reduces Stock Position in Eli Lilly and Company (NYSE:LLY)

American Financial Advisors LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 29.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,377 shares of the company's stock after selling 5,651 shares during the quarter. Eli Lilly and Company accounts for 1.5% of American Financial Advisors LLC's portfolio, making the stock its 22nd biggest holding. American Financial Advisors LLC's holdings in Eli Lilly and Company were worth $10,407,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of LLY. Norges Bank purchased a new position in Eli Lilly and Company during the 4th quarter valued at $5,992,890,000. International Assets Investment Management LLC lifted its holdings in shares of Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company's stock worth $42,802,530,000 after buying an additional 7,330,815 shares during the period. Sapient Capital LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth $682,139,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter worth $435,736,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company's stock worth $37,908,273,000 after buying an additional 659,838 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company's stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the sale, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $8.64 during trading hours on Friday, hitting $733.51. 2,009,249 shares of the stock traded hands, compared to its average volume of 2,265,427. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm's 50 day moving average price is $761.79 and its 200-day moving average price is $666.67. The stock has a market capitalization of $696.95 billion, a price-to-earnings ratio of 126.47, a P/E/G ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $380.77 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the previous year, the business earned $2.09 EPS. The company's quarterly revenue was up 28.1% compared to the same quarter last year. As a group, equities analysts expect that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on LLY shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. DZ Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an "overweight" rating in a research report on Friday, March 15th. Morgan Stanley boosted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an "overweight" rating in a research report on Friday, February 16th. Finally, Bank of America boosted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.